Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4–6: Unsplicing a Conflict

European Urology

Volume 71, Issue 1, January 2017, Pages 6-7

The Anneliese Pohl Foundation sponsored the study and played a role in study design and conduct. The authors have nothing further to disclose.

E.S. Antonarakis et al.
Do patients with AR-V7–positive prostate cancer benefit from novel hormonal therapies? It all depends on definitions
Eur Urol
(2017)
C. Bernemann et al.
Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer
Eur Urol
(2017)
J.S. de Bono et al.
Abiraterone and increased survival in metastatic prostate cancer
N Engl J Med
(2011)
H.I. Scher et al.
Increased survival with enzalutamide in prostate cancer after chemotherapy
N Engl J Med
(2012)
M. Arya et al.
Basic principles of real-time quantitative PCR
Expert Rev Mol Diagn
(2005)

There are more references available in the full text version of this article.